Targets › CLL1
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Mar 2027.
Myeloid inhibitory C-type lectin receptor that acts as a negative regulator of myeloid cell activation. Myeloid cell inhibition is required to limit pro-inflammatory pathways and protect against excessive inflammation (By similarity). (UniProt, Q5QGZ9)
Open in Phaseline: the race on CLL1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | anti-CLL-1 CAR NK cells anti-CLL-1 chimeric antigen receptor NK cells | CLL1 | Phase 1 | Relapsed Adult AML | Mar 2027 |
Relapsed Adult AML (1)
other (1)
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.